Mills Kenneth T. 4
4 · REGENXBIO Inc. · Filed Jul 26, 2024
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
Mills Kenneth T.
Director
Transactions
- Sale
Common Stock
2024-07-25$13.96/sh−15,369$214,501→ 408,035 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-07-25−15,369→ 51,354 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (15,369 underlying) - Exercise/Conversion
Common Stock
2024-07-25$3.76/sh+15,369$57,787→ 423,404 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-07-24−12,221→ 66,723 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (12,221 underlying) - Sale
Common Stock
2024-07-24$13.78/sh−12,221$168,433→ 408,035 total - Exercise/Conversion
Common Stock
2024-07-24$3.76/sh+12,221$45,951→ 420,256 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $13.76 to $13.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $13.76 to $14.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.